Health Technology AnGes, Inc. Business Summary
AnGes, Inc. engages in the research and development of gene-based medical products. It offers genetic medicines such as hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, and others. It is also involved in the research and development of medical equipment, which improves blood circulation by regenerating blood vessels and NfkB which controls various inflammations. The company was founded on December 17, 1999 and is headquartered in Ibaraki, Japan.
Financial Highlights
Dec 2021
JPY USD Revenue 64.14M 0.58M Gross Profit -2,410.09M -21.93M Operating income -15,632.08M -142.27M Income before tax -13,735.29M -125.01M Net income -13,675.58M -124.46M EBITDA -13,206.00M -120.19M Diluted EPS -92.85 -0.84 Dividends Per Share 0 0 Total Assets 45,455.74M 394.73M Total liabilities 6,821.00M 59.23M Total equity 38,634.74M 335.50M Operating cash flow -11,380.54M -103.57M Currency in JPY Currency in USD
Historical Data Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Revenue
365.18M
610.05M
326.75M
39.99M
64.14M
Gross Profit
163.69M
418.87M
235.16M
12.06M
-2,410.09M
Operating income
-3,288.68M
-3,065.25M
-3,270.00M
-5,599.39M
-15,632.08M
Income before tax
-3,744.18M
-3,003.00M
-3,751.60M
-4,204.95M
-13,735.29M
Net income
-3,764.69M
-2,996.62M
-3,750.82M
-4,209.51M
-13,675.58M
EBITDA
-3,259.32M
-3,057.39M
-3,262.68M
-5,591.80M
-13,206.00M
Diluted EPS
-49.38
-34.46
-35.81
-35.32
-92.85
Dividends Per Share
0
0
0
0
0
Total Assets
3,963.60M
8,050.67M
12,524.60M
38,354.61M
45,455.74M
Total liabilities
341.72M
316.21M
469.24M
5,674.93M
6,821.00M
Total equity
3,621.88M
7,734.45M
12,055.35M
32,679.67M
38,634.74M
Operating cash flow
-2,991.22M
-2,522.50M
-2,179.91M
-2,961.32M
-11,380.54M
Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Revenue
3.25M
5.52M
2.99M
0.37M
0.58M
Gross Profit
1.45M
3.79M
2.15M
0.11M
-21.93M
Operating income
-29.32M
-27.75M
-29.99M
-52.44M
-142.27M
Income before tax
-33.39M
-27.19M
-34.41M
-39.38M
-125.01M
Net income
-33.57M
-27.13M
-34.40M
-39.42M
-124.46M
EBITDA
-29.06M
-27.68M
-29.92M
-52.37M
-120.19M
Diluted EPS
-0.44
-0.31
-0.32
-0.33
-0.84
Dividends Per Share
0
0
0
0
0
Total Assets
35.18M
73.37M
115.24M
371.49M
394.73M
Total liabilities
3.03M
2.88M
4.31M
54.96M
59.23M
Total equity
32.15M
70.49M
110.93M
316.52M
335.50M
Operating cash flow
-26.67M
-22.83M
-19.99M
-27.73M
-103.57M
Valuation Measures
Dec 2021
PER -- ROA -32.63% ROE -38.35% Operating margin -24,368.77% Profit margin -21,318.80%
Key executives
President & Representative Director:
Ei Yamada
Director, Executive Officer & Manager-Finance:
Tetsuji Yoneo
Director & Manager-Drug Discovery Research:
Kazuo Suzuki
Executive Officer, Manager-R&D Promotion:
Hajime Watanabe
Manager-Accounting:
Jun Sakurai Shareholders
OrbiMed Advisors Private Equity (3.8%)
BlackRock Fund Advisors (1.3%)
Shionogi & Co., Ltd. (0.7%)
MORISHITA RYUICHI (0.4%)
BlackRock Advisors (UK) Ltd. (0.2%)
TIAA-CREF Investment Management LLC (0.1%)
SSgA Funds Management, Inc. (0.0%)
Geode Capital Management LLC (0.0%)
Credit Suisse Asset Management (Schweiz) AG (0.0%)
ISHIHARA SANGYO KAISHA LTD. (0.0%)
Contact Details Website: http://www.anges.co.jp Address:
Saito Bio-Incubator, 1/F,
7-7-15 Saito-Asagi,
Osaka,
567-0085,
Japan
Phone:
+81.72.643.3590
Related Companies
Emendo Biotherapeutics, Inc.
AnGes USA, Inc.
AnGes Euro Ltd.
Competitors
Sienna Biopharmaceuticals, Inc.
Athira Pharma, Inc.
Copyright © 2022 FactSet Research Systems Inc. All rights reserved.
Last Updated on 24 May, 2022
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapter
Free access for everyone - Sep. 30
Find out more
By continuing to browse this website, you accept cookies which are used for several reasons such as personalizing content/ads and analyzing how this website is used. Please review our
Cookie Policy
to learn how you can update your cookie settings.
Accept & Continue
Close